Grant from the Gates Foundation to investigate efficient targeted DNA insertion
Advance use of proprietary platform for next generation gene therapy applications
CAMBRIDGE, UK, May 28, 2025 / Biotech Newswire / -- Gene Weaver Ltd (Gene Weaver), a biology technology innovator, has received $515,214 from the Gates Foundation to support the development of a next generation gene insertion tool. The grant will support work on Gene Weaver’s gene editing platform, and its potential to enable a low-cost option for protein therapeutics in low- and middle-income countries (LMIC).
Cambridge-based Gene…
Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions
Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions
Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies
Cambridge, UK and Marlborough, MA, 28 May 2025…
Amsbio has expanded its range of high-quality antibodies supporting standardization and Quality Assurance in the fast-growing stem cell research and therapeutic field. These optimized antibodies ensure reliable, accurate results in applications including flow cytometry, immunocytochemistry, Western blot, and ELISA.
New additions to the range include monoclonal antibodies against key pluripotent stem cell markers: SSEA-3 (Gb5), SSEA-4 (SialylGb5), and Lewis X (SSEA-1). Stage-Specific Embryonic Antigens (SSEA) are glycan antigens known to vary in their…
Studies presented at leading ophthalmology and gene therapy conferences demonstrate therapeutic potential in geographic atrophy and wet AMD, leading causes of legal blindness
This single-administration gene therapy approach could replace frequent eye injections for geographic atrophy and wet AMD patients
The lead candidate IKAR-001 (previously known as IKC159V) will proceed to a geographic atrophy clinical trial supported by studies showing preservation of cells critical for vision
Norwich, UK, May 28 2025 – Ikarovec, a leader in ophthalmology innovation with a sophisticated field-…
Sandwich, UK - 28 May 2025: Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.
Partnered with health-specialist venture capital firm Zinc, the initiative offers expert-led business skills sessions and the opportunity to secure £250k Zinc investment.
Discovery Spark is a transformative business programme for early-stage startups, led by science and tech hub Discovery Park. With practical sessions bridging the gap between science and business, Discovery Spark…
Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.
MDC’s Chemical Protein Stability Assay (CPSA) is a distinctive technology used to assess target engagement. It can be applied at every step of the drug discovery process to support drug development, screening, and optimisation.
Target engagement is a key step in early-stage drug discovery. By understanding the relationship between drug/target binding and efficacy, innovators…
Creative Biolabs is dedicated to helping researchers overcome gene therapy delivery research challenges with its wide technical support and services.Gene therapy is highly promising for the treatment of numerous genetic disorders, but there are significant restrictions on its application to effective clinical interventions. Most prominent among these is the development of efficient and safe systems of gene delivery, both viral and non-viral vectors.Creative Biolabs has recently enhanced its technology platform to enable viral vector manufacturing from small to large scales with good titers,…
• Maxion Therapeutics expands its Cambridge headquarters and doubles the size of its offices and laboratory space• Howard Group provides tailored real estate solution to support the biotech’s growthCambridge, 20th May 2025: Leading regional property investor and developer Howard Group, is delighted to announce that pioneering biotechnology company Maxion Therapeutics has more than doubled its footprint at Unity Campus.Following its successful £58 million ($72 million) Series A funding round earlier this year, Maxion has signed a new lease for…
Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion
Cambridge, UK, 20 May 2025: CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea. The agreement is the latest milestone in CN Bio’s international expansion, amplifying the Company’s presence in major Asian and Pacific markets and broadening access to its predictive…
Creative Biolabs is at the forefront of creating stem cell therapy, working with researchers to make new scientific advancements.Induced pluripotent stem cells (iPSCs) contain the unprecedented possibility of differentiating into almost every cell in the body, which holds vast avenues for disease studying and developing novel therapies. Nonetheless, iPSC-based cell therapy is presently problematic. Issues like low reprogramming efficiency, genomic instability, risk of tumorigenicity, and failure in controlling differentiation encompass significant setbacks.Creative Biolabs, a US biotech firm…